Heart Failure in Hospital Medicine: An Evidence-Based Guide for Hospitalists

Heart failure is one of the most important conditions hospitalists manage.

But “heart failure admission” describes a remarkably diverse group of patients.

One patient arrives hypertensive with acute pulmonary edema.

Another has slowly progressive peripheral edema and ascites.

Another has worsening renal function, borderline blood pressure, and persistent congestion.

Another has newly recognized HFrEF.

Another has HFpEF complicated by atrial fibrillation.

And a small but critically important group presents with cardiogenic shock.

These patients should not all be managed the same way.

For hospitalists, inpatient heart failure management requires answering several questions:

Is this actually acute heart failure?

Is the patient congested?

Is perfusion adequate?

What precipitated the decompensation?

Is the patient responding to therapy?

Which long-term therapies should be continued, initiated, or optimized?

Is the patient truly ready for discharge?

This guide reviews a practical, evidence-based approach to hospitalized heart failure.

Clinical note: This article is intended for professional education, not patient-specific medical advice. Heart failure management must be individualized according to hemodynamics, kidney function, comorbidities, contraindications, clinical trajectory, current guidelines, and local protocols.

What Is Heart Failure?

Heart failure is a clinical syndrome caused by structural or functional cardiac abnormalities that result in symptoms and signs associated with elevated filling pressures and/or inadequate cardiac output.

The syndrome is classified partly according to left ventricular ejection fraction.

HFrEF

Heart failure with reduced ejection fraction

LVEF ≤40%

HFmrEF

Heart failure with mildly reduced ejection fraction

LVEF 41–49%

HFpEF

Heart failure with preserved ejection fraction

LVEF ≥50%

HFimpEF

Heart failure with improved ejection fraction

Previous LVEF ≤40% with a subsequent measurement >40%.

This distinction matters because long-term evidence-based therapy differs across these groups.

But during hospitalization, ejection fraction is only part of the story.

The immediate questions are often:

Is the patient wet or dry?

and:

Is the patient warm or cold?

The Hospitalist’s First Task: Establish the Syndrome

Dyspnea plus edema does not automatically equal heart failure.

The differential may include:

• Pneumonia
• COPD exacerbation
• Pulmonary embolism
• Acute coronary syndrome
• Renal failure
• Cirrhosis
• Nephrotic syndrome
• Severe anemia
• Medication effects
• Venous disease

Several of these conditions can coexist with heart failure.

Avoid treating the BNP rather than the patient.

Symptoms of Acute Heart Failure

Common presenting symptoms include:

• Dyspnea
• Orthopnea
• Paroxysmal nocturnal dyspnea
• Exercise intolerance
• Fatigue
• Peripheral edema
• Weight gain
• Abdominal distention
• Early satiety

More severe presentations may include:

• Acute pulmonary edema
• Respiratory failure
• Hypotension
• Altered mental status
• Oliguria
• Evidence of cardiogenic shock

The pattern matters.

A patient with gradually worsening edema over two weeks represents a different physiologic problem from someone who develops severe hypertension and pulmonary edema over several hours.

Look for Congestion and Perfusion

A useful bedside framework classifies the patient according to congestion and perfusion.

Congestion: “Wet” or “Dry”?

Look for evidence such as:

• Elevated jugular venous pressure
• Peripheral edema
• Pulmonary congestion
• Orthopnea
• Ascites
• Hepatic congestion
• Weight gain

No single finding is perfect.

Volume assessment requires integrating the history, examination, imaging, laboratory information, urine output, weight trajectory, and response to treatment.

Perfusion: “Warm” or “Cold”?

Signs concerning for impaired perfusion may include:

• Cool extremities
• Narrow pulse pressure
• Hypotension
• Altered mentation
• Oliguria
• Rising lactate in the appropriate context
• Evidence of end-organ dysfunction

Most hospitalized patients with decompensated heart failure are congested but adequately perfused.

The “cold” patient deserves particular attention because low output may substantially change management.

Don’t Miss Cardiogenic Shock

Cardiogenic shock is not simply:

heart failure plus a low blood pressure.

It is a syndrome of inadequate cardiac output resulting in tissue hypoperfusion.

Possible findings include:

• Hypotension
• Cool extremities
• Altered mental status
• Oliguria
• Elevated lactate
• Worsening kidney or liver function
• Narrow pulse pressure
• Persistent tachycardia

Some patients can have clinically important hypoperfusion without profound hypotension.

If cardiogenic shock is suspected, rapidly reassess:

• Etiology
• Hemodynamics
• ECG
• Echocardiography
• Ischemia
• Mechanical complications
• Arrhythmias
• Volume status

These patients may require intensive care, cardiology or advanced heart-failure involvement, vasoactive therapy, invasive hemodynamic assessment, and mechanical circulatory support in selected circumstances.

Do not allow a routine “CHF exacerbation” label to delay recognition of a much higher-risk syndrome.

Initial Evaluation of Hospitalized Heart Failure

The initial workup should answer several questions simultaneously.

Is Heart Failure the Correct Diagnosis?

Use the clinical picture together with appropriate testing.

Evaluation commonly includes:

• ECG
• Chest imaging
• CBC
• Electrolytes
• Kidney function
• Liver tests when appropriate
• BNP or NT-proBNP when diagnostically useful
• Troponin when clinically indicated
• Echocardiography when needed

Remember that natriuretic peptides are influenced by factors such as:

• Age
• Kidney dysfunction
• Atrial fibrillation
• Obesity

Interpret the number within the clinical context.

What Is the Ejection Fraction?

Determine whether the patient has:

• HFrEF
• HFmrEF
• HFpEF
• HFimpEF

If there is no recent reliable assessment of cardiac structure and function—or the clinical situation suggests a meaningful change—echocardiography may be appropriate.

Is There an Immediately Dangerous Trigger?

Consider:

• Acute coronary syndrome
• Rapid arrhythmia
• Severe bradyarrhythmia
• Hypertensive emergency
• Infection
• Pulmonary embolism
• Acute valvular disease
• Myocarditis
• Mechanical complications of MI

These conditions may require treatment beyond routine decongestion.

What Caused the Decompensation?

Identifying a precipitating factor is important, but avoid assuming every admission occurred because the patient “wasn’t compliant.”

Common contributors include:

• Ischemia
• Arrhythmia
• Infection
• Uncontrolled hypertension
• Progressive kidney dysfunction
• Medication changes
• NSAID exposure
• Inadequate outpatient diuretic effect
• Dietary factors
• Difficulty accessing medications
• Inability to follow a complex regimen
• Progression of underlying cardiac disease

Some admissions do not have a single identifiable precipitant.

And what looks like “nonadherence” may actually reflect:

• Cost
• Health literacy
• Transportation
• Pharmacy access
• Adverse effects
• Cognitive impairment
• Housing instability
• Complicated dosing

Understanding why a treatment plan failed is more useful than simply documenting that it failed.

Decongestion Is a Central Inpatient Goal

For patients admitted with significant volume overload, decongestion is central to treatment.

Loop diuretics remain foundational therapy.

The specific dose should be individualized according to factors such as:

• Previous diuretic exposure
• Degree of congestion
• Kidney function
• Blood pressure
• Prior response
• Clinical severity

The important question after giving a diuretic is not simply:

Did I order furosemide?

It is:

Did the patient respond?

Assess the Diuretic Response Early

After initiating IV loop-diuretic therapy, reassess.

Consider:

• Urine output
• Symptoms
• Physical examination
• Weight trajectory
• Kidney function
• Electrolytes
• Blood pressure

If the response is inadequate, do not continue the same ineffective strategy indefinitely.

Depending on the clinical situation, options may include:

• Increasing the loop-diuretic dose
• Adjusting frequency
• Sequential nephron blockade
• Adding another diuretic strategy in selected patients
• Reassessing whether congestion is truly present
• Reassessing perfusion and hemodynamics

Persistent congestion should prompt clinical reassessment rather than therapeutic inertia.

What About Acetazolamide?

Acetazolamide has received renewed attention as an adjunct to loop diuretics in acute decompensated heart failure.

Evidence supports improved decongestion in selected hospitalized patients when acetazolamide is added to loop-diuretic therapy.

That does not mean every patient with heart failure should automatically receive it.

Consider:

• Patient selection
• Acid-base status
• Electrolytes
• Kidney function
• Existing diuretic response
• Local protocols

Adjunctive therapy should solve a specific clinical problem rather than simply add another medication.

Rising Creatinine During Diuresis: Don’t React to One Number in Isolation

One of the most common inpatient dilemmas is:

The patient is still congested, but the creatinine increased. Should I stop diuresis?

Not necessarily.

A modest change in creatinine during effective decongestion does not automatically mean treatment should stop.

The more useful question is:

What is happening to the patient?

Assess:

• Residual congestion
• Blood pressure
• Perfusion
• Urine output
• Electrolytes
• Magnitude and trajectory of kidney-function change
• Potential nephrotoxins
• Alternative causes of AKI

If the patient remains substantially congested and otherwise hemodynamically stable, reflexively stopping decongestion because of a small creatinine increase may leave the primary problem untreated.

Conversely, worsening kidney function accompanied by hypotension, poor perfusion, severe electrolyte abnormalities, or other evidence of instability demands reassessment.

Treat the physiology, not an isolated laboratory value.

Monitor Electrolytes Carefully

Diuresis can produce clinically important changes in:

• Potassium
• Magnesium
• Sodium
• Bicarbonate
• Kidney function

Monitoring frequency should reflect:

• Diuretic intensity
• Baseline kidney function
• Clinical instability
• Electrolyte abnormalities
• Concomitant therapies

Electrolyte management is not simply a laboratory exercise.

Abnormal potassium and magnesium levels can have important arrhythmic consequences.

Oxygen Is for Hypoxemia

Do not use supplemental oxygen automatically because a patient has heart failure.

Provide oxygen when clinically indicated for hypoxemia.

Patients with severe acute pulmonary edema and respiratory distress may benefit from noninvasive positive-pressure ventilation when appropriate.

Patients requiring escalating respiratory support should also prompt reassessment of the underlying hemodynamics and cause of deterioration.

Hypertensive Acute Heart Failure

Some patients present with severe hypertension and acute pulmonary congestion.

Their physiology may differ from that of a patient with gradual systemic volume accumulation.

In appropriately selected patients with adequate blood pressure, vasodilator therapy may help reduce filling pressures and afterload.

The treatment strategy should reflect the hemodynamic phenotype.

Do not manage every “wet” patient identically.

What About Fluid and Sodium Restriction?

Routine restrictions should not become automatic rituals disconnected from the patient’s physiology.

The appropriate approach depends on factors such as:

• Congestion
• Serum sodium
• Diuretic response
• Thirst
• Kidney function
• Individual clinical circumstances

Avoid turning a generic “2-liter fluid restriction” into a substitute for thoughtful assessment.

HFrEF: Hospitalization Is an Opportunity for GDMT

One of the biggest changes in contemporary inpatient heart-failure management is the emphasis on using hospitalization to establish evidence-based long-term therapy when clinically feasible.

For eligible patients with HFrEF, guideline-directed medical therapy is built around four foundational medication classes:

1. ARNI, ACE inhibitor, or ARB
2. Evidence-based beta-blocker
3. Mineralocorticoid receptor antagonist
4. SGLT2 inhibitor

The goal is not necessarily to achieve target doses of every medication before discharge.

The goal is to avoid unnecessarily leaving major evidence-based therapies unaddressed.

Don’t Think Only in Terms of Sequential Titration

Historically, clinicians often started one medication, increased it toward target dose, and only later considered adding another class.

Contemporary HFrEF management emphasizes establishing the foundational medication classes relatively early when tolerated.

Why?

Because the benefits arise from complementary mechanisms.

A patient receiving a high dose of one medication is not necessarily receiving the same protection as a patient receiving appropriate therapy across several foundational classes.

Hospitalization can provide an opportunity to begin closing those gaps.

SGLT2 Inhibitors Have Changed Inpatient Heart Failure Management

SGLT2 inhibitors are now an important component of heart-failure therapy.

Their benefit is not limited to patients with diabetes.

For eligible patients with HFrEF, they are one of the four foundational GDMT classes.

They also have an important role across the broader EF spectrum.

Current ACC inpatient guidance supports consideration of SGLT inhibition during hospitalization, including across ejection-fraction categories, when clinically appropriate.

Before initiation, consider factors such as:

• Kidney function and current prescribing criteria
• Hemodynamic stability
• Volume status
• Risk of ketoacidosis
• Acute illness context
• Perioperative considerations
• Cost and access

“Start an SGLT2 inhibitor” is not a substitute for patient selection.

Beta-Blockers During Acute Decompensation

A common hospital question is whether to continue the patient’s beta-blocker.

The answer depends on clinical status.

In a patient with decompensated heart failure who remains adequately perfused and does not have another contraindication, continuation may be appropriate.

In a patient with:

• Cardiogenic shock
• Significant hypoperfusion
• Severe bradycardia
• Other major intolerance

the approach may be different.

Similarly, initiation or up-titration should reflect the patient’s trajectory and hemodynamic stability.

Do not reduce beta-blocker management to:

“always continue”

or:

“always hold during decompensation.”

RAAS Inhibition and ARNI Therapy

For eligible patients with HFrEF, renin-angiotensin system inhibition remains foundational.

ARNI is preferred for many patients with symptomatic HFrEF when feasible.

But inpatient initiation or continuation depends on:

• Blood pressure
• Kidney function
• Potassium
• Previous tolerance
• Contraindications
• Clinical trajectory

A temporary contraindication during severe acute illness should not automatically become permanent omission at discharge.

If therapy cannot be initiated, document why and create a follow-up plan.

Mineralocorticoid Receptor Antagonists

MRAs are another foundational therapy for eligible HFrEF patients.

Before initiation, evaluate:

• Kidney function
• Potassium
• Ability to obtain follow-up laboratory monitoring
• Contraindications

Hospitalization can be a useful opportunity to identify eligible patients who have never been started on therapy.

But safe outpatient monitoring must be part of the plan.

HFpEF Is Not “Heart Failure With Nothing to Do”

HFpEF management historically had fewer disease-modifying options than HFrEF.

That landscape has changed.

SGLT2 inhibitors have become an important evidence-based therapy for appropriate patients with HFpEF.

Hospitalists should also identify and manage major contributors and comorbidities such as:

• Hypertension
• Atrial fibrillation
• Coronary disease
• Obesity
• Diabetes
• Kidney disease
• Sleep-disordered breathing where relevant

And during acute hospitalization:

congestion still needs to be treated.

Preserved ejection fraction does not mean preserved clinical status.

HFmrEF Also Deserves Attention

Patients with an EF of 41–49% should not simply disappear into a therapeutic gray zone.

SGLT2 inhibition has an evidence-based role in this population.

Other therapies used for HFrEF may be considered in selected patients, particularly toward the lower end of the EF range and depending on individual circumstances.

Review previous imaging whenever possible.

A patient currently classified as HFmrEF may actually have:

• Improving HFrEF
• Worsening HFpEF
• Measurement variability

The trajectory matters.

Don’t Stop GDMT Simply Because EF Improved

A patient whose EF has recovered may be described as having heart failure with improved ejection fraction.

Improved EF does not necessarily mean the underlying disease has disappeared.

Current guidance generally supports continuing HFrEF GDMT in patients with HFimpEF to reduce the risk of relapse.

Before discontinuing long-term therapy because an echocardiogram “looks normal,” understand the patient’s previous phenotype and why the EF improved.

Atrial Fibrillation and Heart Failure

Atrial fibrillation frequently coexists with heart failure.

During hospitalization, consider:

• Is AF causing the decompensation?
• Is it a consequence of worsening filling pressures?
• Is ventricular rate contributing to symptoms?
• Is rhythm control appropriate?
• Is anticoagulation indicated?
• Are there medication interactions or contraindications?

Avoid treating the heart rate without asking whether the rhythm is part of the reason the patient is hospitalized.

Ischemia and Heart Failure

Acute coronary syndrome may precipitate acute heart failure.

Evaluate for ischemia based on:

• Symptoms
• ECG
• Troponin pattern
• Hemodynamics
• Clinical context

Troponin elevation alone does not establish type 1 myocardial infarction.

Patients with acute heart failure may have myocardial injury for several reasons.

Interpret the result rather than treating the laboratory value in isolation.

Iron Deficiency Matters

Iron deficiency is common in heart failure and may contribute to symptoms and functional limitation.

Current heart-failure management includes attention to iron status in appropriate patients.

Hospitalization may provide an opportunity to recognize previously unaddressed iron deficiency and determine whether treatment is appropriate.

The evaluation and treatment strategy should follow current heart-failure guidance rather than simply treating any low hemoglobin as iron deficiency.

Don’t Forget Medication Review

Several medications can worsen heart failure or complicate its management in selected patients.

Medication reconciliation should look beyond whether the patient remembers taking the prescribed diuretic.

Review for:

• NSAIDs
• Drugs that contribute to sodium or fluid retention
• Negative inotropic medications when relevant
• Duplicative therapies
• Medication interactions
• Medications limited by kidney function
• Cost barriers
• Complex dosing schedules

The discharge medication list should be treated as a clinical intervention.

Decongestion and GDMT Are Not Competing Goals

A common mistake is thinking:

First we diurese. Then, after the patient is completely finished with acute treatment, we think about long-term therapy.

Contemporary inpatient heart-failure care is more integrated.

During hospitalization, clinicians repeatedly reassess:

• Congestion
• Perfusion
• Kidney function
• Blood pressure
• Clinical trajectory
• Long-term therapy

As the patient stabilizes and approaches decongestion, opportunities to establish GDMT increase.

The two processes overlap.

Reassess the Clinical Trajectory

A useful inpatient question is:

Is this patient improving, stalled, or worsening?

Improving

If symptoms, congestion, perfusion, kidney function, and hemodynamics are moving in the right direction, continue advancing toward:

• Decongestion
• Stable oral therapy
• GDMT optimization
• Discharge planning

Stalled

If progress stops, reconsider:

• Diagnosis
• Volume assessment
• Diuretic strategy
• Medication effects
• Kidney function
• Arrhythmia
• Ischemia
• Infection
• Hemodynamics

Worsening

Clinical deterioration should trigger broader reassessment.

Consider whether the patient has:

• Cardiogenic shock
• New ischemia
• Arrhythmia
• Mechanical complication
• Progressive organ dysfunction
• An incorrect initial diagnosis

Repeating the same treatment while the patient worsens is not a strategy.

When Should You Consider Hemodynamic Assessment?

Most patients admitted with heart failure do not require invasive hemodynamic monitoring.

But it may be useful in selected patients when the clinical picture remains uncertain or when management depends on understanding filling pressures and cardiac output more precisely.

Potential scenarios include:

• Uncertain volume status
• Persistent symptoms despite treatment
• Suspected low-output state
• Shock
• Conflicting clinical data
• Advanced heart failure evaluation

The test should answer a management question.

When Should Hospitalists Involve Cardiology?

Not every heart-failure admission requires cardiology consultation.

But early involvement may be appropriate when there is:

• Cardiogenic shock
• New severe cardiomyopathy
• Suspected acute coronary syndrome
• Significant valvular disease
• Refractory congestion
• Difficult arrhythmia
• Uncertain diagnosis
• Recurrent admissions despite therapy
• Potential need for advanced therapies
• Device-related questions

The purpose of consultation should be specific.

Recognize Advanced Heart Failure

Some patients are not experiencing an isolated exacerbation.

They are demonstrating progression of the underlying disease.

Warning signs may include:

• Repeated hospitalizations
• Escalating diuretic requirements
• Persistent hypotension
• Worsening kidney function
• Intolerance of GDMT
• Progressive functional limitation
• Recurrent need for inotropes
• Evidence of low output

These patients may need evaluation for:

• Advanced heart-failure therapies
• Mechanical circulatory support
• Transplantation
• Palliative care
• Goals-of-care planning

The correct response to advanced disease is not simply another identical admission-and-discharge cycle.

Palliative Care Belongs in Heart Failure Care

Palliative care is not synonymous with stopping treatment.

Patients with advanced heart failure may benefit from attention to:

• Symptom burden
• Prognostic understanding
• Treatment preferences
• Caregiver needs
• Advance care planning
• Goals of care

These discussions can occur alongside disease-directed treatment.

For patients with advanced or repeatedly decompensated heart failure, avoiding the subject because “they aren’t hospice yet” misses the purpose of palliative care.

Discharge Planning Begins Before Discharge Day

Heart-failure discharge planning should begin early.

Waiting until the final morning to address:

• Medications
• Insurance authorization
• Follow-up
• Transportation
• Education
• Laboratory monitoring

creates avoidable problems.

Heart failure is also a good example of why delayed hospital discharges are often system problems involving multiple teams rather than simply physician inefficiency.

What Should Be True Before Discharge?

There is no single laboratory value or physical finding that establishes readiness for discharge.

Instead, assess whether:

• Acute symptoms have meaningfully improved
• Congestion has been adequately addressed
• Hemodynamics are stable
• The oral diuretic strategy is reasonable
• Electrolytes and kidney function are acceptable for the plan
• GDMT has been reviewed
• Major contraindications or omissions are documented
• Medication access has been considered
• Follow-up is arranged
• Necessary laboratory monitoring is planned
• The patient understands the medication plan and warning symptoms

“Feels better” is not enough.

Neither is:

“Length of stay is three days, so it’s time to go.”

Residual Congestion Matters

Patients may feel substantially better before they are adequately decongested.

Dyspnea can improve early.

That does not necessarily mean the physiologic problem has resolved.

Before discharge, reassess for residual congestion using the complete clinical picture.

The goal is not to achieve an arbitrary “dry weight” at all costs.

It is to leave the patient with a clinically appropriate volume status and a workable outpatient plan.

Create a Real Diuretic Plan

Do not simply resume the preadmission outpatient dose without asking whether it was working.

Before discharge, determine:

• What oral regimen is appropriate?
• Did the patient respond to it?
• What should happen if weight or symptoms increase?
• When should kidney function and electrolytes be checked?
• Who will review those results?

A prescription without a monitoring plan is incomplete care.

Medication Access Is Part of GDMT

It is easy to write:

Start ARNI.

Start SGLT2 inhibitor.

Start MRA.

It is harder to determine whether the patient can actually obtain and continue them.

Before discharge, consider:

• Insurance coverage
• Copays
• Prior authorization
• Pharmacy access
• Health literacy
• Ability to monitor blood pressure
• Ability to obtain laboratory testing

The theoretically ideal regimen is not useful if the patient cannot obtain it.

Communicate the Hospital Course

The discharge summary should make the heart-failure plan understandable to the next clinician.

Include important information such as:

• Why the patient was admitted
• Suspected precipitating factors
• EF and relevant cardiac findings
• Major treatment provided
• Diuretic response
• Discharge volume assessment
• Medication changes
• Why medications were stopped or deferred
• Required laboratory monitoring
• Follow-up needs
• Unresolved questions

Transitions fail when the reasoning disappears at discharge.

Early Follow-Up Matters

Heart-failure management does not end when the patient leaves the hospital.

The early post-discharge period may require:

• Symptom assessment
• Weight review
• Blood-pressure review
• Kidney-function testing
• Electrolyte monitoring
• Diuretic adjustment
• GDMT initiation or titration
• Medication-access troubleshooting

The inpatient team should make the next step clear.

Heart Failure and Hospital Length of Stay

Hospitalists frequently face pressure to reduce length of stay.

The objective should be appropriate length of stay, not simply the shortest possible hospitalization.

A patient should not remain hospitalized because routine processes are inefficient.

But a patient also should not be discharged prematurely simply to improve a throughput metric.

Our broader guide to reducing hospital length of stay discusses how patient flow, discharge preparation, multidisciplinary coordination, and safe transitions fit together.

Common Inpatient Heart Failure Mistakes

Mistake 1: Treating Every Dyspneic Patient as Heart Failure

Maintain the differential.

Mistake 2: Ordering Diuretics Without Measuring Response

Treatment needs reassessment.

Mistake 3: Stopping Diuresis Reflexively for Any Creatinine Increase

Interpret kidney function in the context of congestion, perfusion, blood pressure, urine output, and overall trajectory.

Mistake 4: Focusing on Fluid Removal but Ignoring the Trigger

Ask why the patient decompensated.

Mistake 5: Calling Every Trigger “Noncompliance”

Investigate medication access, side effects, health literacy, social barriers, and disease progression.

Mistake 6: Waiting Until Discharge Day to Think About GDMT

Hospitalization is an opportunity to establish evidence-based therapy when clinically appropriate.

Mistake 7: Assuming HFpEF Has No Disease-Modifying Therapy

Contemporary management includes SGLT2 inhibitors for appropriate patients and aggressive attention to relevant comorbidities.

Mistake 8: Stopping GDMT Because EF Improved

HFimpEF does not automatically mean heart failure has resolved.

Mistake 9: Discharging Because Dyspnea Improved

Residual congestion and the complete discharge plan still matter.

Mistake 10: Ignoring Medication Access

The patient has to be able to obtain the regimen.

10 High-Yield Heart Failure Pearls for Hospitalists

1. Phenotype before protocol.

Determine congestion and perfusion before treating every heart-failure patient identically.

2. Decongestion is a major inpatient objective.

But measure the response rather than merely ordering a diuretic.

3. A creatinine increase is information—not an automatic stop signal.

Interpret it within the patient’s complete trajectory.

4. HFrEF treatment is built around four foundational GDMT classes.

Think across classes rather than focusing only on maximizing one drug.

5. Hospitalization can be an opportunity to establish GDMT.

Don’t automatically defer every long-term therapy decision to outpatient follow-up.

6. SGLT2 inhibitors are heart-failure drugs, not simply diabetes drugs.

Their role extends across the EF spectrum in appropriate patients.

7. HFpEF is not “nothing to treat.”

Treat congestion, consider evidence-based therapies, and aggressively address important comorbidities.

8. Improved EF does not necessarily mean cured heart failure.

Understand the previous phenotype before withdrawing therapy.

9. Discharge planning begins early.

Medication access, monitoring, follow-up, and patient understanding take time.

10. Recurrent admissions may signal disease progression.

Sometimes the right question is no longer “How do we treat this exacerbation?” but “Where is this patient’s heart failure trajectory going?”

A Practical Hospitalist Framework

When admitting a patient with suspected acute heart failure, work through these questions:

1. Is this actually heart failure?

Maintain a differential.

2. What is the EF phenotype?

HFrEF, HFmrEF, HFpEF, or HFimpEF?

3. Is the patient congested?

Assess the complete clinical picture.

4. Is perfusion adequate?

Look for low-output physiology.

5. Is there cardiogenic shock?

Recognize it early.

6. What precipitated the hospitalization?

Look beyond “noncompliance.”

7. Is the patient responding to decongestion?

Measure response and adjust.

8. What is happening to kidney function and electrolytes?

Interpret changes physiologically.

9. Which GDMT is already present?

Identify gaps and contraindications.

10. What can safely be initiated or optimized before discharge?

Use the hospitalization as an opportunity.

11. Is the patient genuinely ready to leave?

Assess congestion, stability, medication plan, access, and follow-up.

12. What happens next?

Create an explicit monitoring and follow-up plan.

That framework is more useful than memorizing a single “CHF order set.”

Heart Failure Guidance Hospitalists Should Know in 2026

An important point for clinicians searching for a “2026 heart failure guideline”:

As of 2026, the major comprehensive U.S. heart-failure guideline remains the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

The ACC subsequently published a 2024 Expert Consensus Decision Pathway focused on patients hospitalized with heart failure, incorporating newer evidence and placing greater emphasis on:

• Effective decongestion
• Reassessment according to clinical trajectory
• Establishing the four HFrEF GDMT pillars during hospitalization when feasible
• Use of SGLT inhibitors during the inpatient pathway
• Detailed discharge planning
• Post-discharge titration and follow-up
• Recognition of advanced disease and goals of care

A comprehensive updated ACC/AHA heart-failure guideline is expected subsequently, so clinicians should verify current recommendations as new guidance is released.

Heart failure is also included in our broader overview of clinical guidelines every hospitalist should know in 2026.

Where CME Fits

Heart failure demonstrates why hospital medicine requires ongoing learning.

The disease itself is familiar.

The therapeutic landscape is not static.

Hospitalists need to remain current on:

• Decongestion strategies
• GDMT
• SGLT2 inhibitors
• HFpEF
• Cardiogenic shock
• Arrhythmias
• Kidney-heart interactions
• Discharge transitions

That does not mean a conference replaces clinical guidelines, primary literature, cardiology consultation, or patient-specific judgment.

CME is one component of a broader learning system.

Clinicians looking for structured inpatient education can review current Hospitalist CME programs and compare the heart-failure and cardiovascular curriculum with their own learning needs.

Final Thoughts

The hospitalist’s role in heart failure extends far beyond ordering IV furosemide.

High-quality inpatient management requires understanding:

Diagnosis.

Congestion.

Perfusion.

Precipitating factors.

Diuretic response.

Kidney function.

GDMT.

Clinical trajectory.

Discharge readiness.

Long-term follow-up.

The most important shift in contemporary inpatient heart-failure care may be recognizing that hospitalization is not merely a brief episode during which symptoms are improved.

It is an opportunity to understand why the patient’s heart failure worsened, achieve appropriate decongestion, identify the direction of the disease, establish evidence-based long-term therapy when feasible, and build a safer transition back to outpatient care.

For more high-yield inpatient medicine review, see our 100 Hospitalist Clinical Pearls.

And for current hospital medicine education, explore upcoming CME Getaways conferences.

Treat the congestion. Understand the trajectory. Don’t waste the hospitalization.

References

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022.

Hollenberg SM, Warner Stevenson L, et al. 2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure: Focused Update. Journal of the American College of Cardiology. 2024.

American College of Cardiology. Heart Failure Hospitalization Pathway Toolkit. Current clinical resources based on the 2024 Expert Consensus Decision Pathway.